Objectives: To evaluate the long-term cost-effectiveness of ticagrelor and ASA versus generic and branded clopidogrel …,055 ($1,946) THB($)/QALY compared with generic and branded clopidogrel, respectively. The probability of ticagrelor being cost …-effective was above 99% at a threshold of 160,000 THB/QALY compared with branded clopidogrel. Conclusions: This health economic …

Objectives: To evaluate the long-term cost-effectiveness of ticagrelor and ASA versus generic and branded clopidogrel …,055 ($1,946) THB($)/QALY compared with generic and branded clopidogrel, respectively. The probability of ticagrelor being cost …-effective was above 99% at a threshold of 160,000 THB/QALY compared with branded clopidogrel. Conclusions: This health economic …

unstable angina (UA). The CURE (Clopidogrel in Unstable angina to prevent Recurrent Events) trial has shown that clopidogrel …:Objective: To evaluate the cost effectiveness of 1 year of treatment with clopidogrel in addition to aspirin in NSTEMI or UA … aspirin treatment group and 8.41 years in the aspirin plus clopidogrel treatment group. The corresponding discounted QALYs …

clopidogrel in Thailand. Based on this analysis, it appears that ticagrelor is an economically valuable treatment for ACS compared … with branded clopidogrel within the Thai context. </AbstractSection> Copyright Yamwong et al.; licensee Springer. 2014 …

adverse cardiac events with clopidogrel, but not with prasugrel. The frequency of the &ast;2 allele varies by ethnicity and … patients with generic clopidogrel compared with prasugrel, and also compared with the genetically guided strategy that &ast;2 … allele carriers receive prasugrel and non-carriers receive clopidogrel. Abstract: Methods:Methods: A decision-tree model …

efficacy in the secondary prevention of atherothrombotic events. Although clopidogrel seems to be superior to aspirin in terms …. Abstract: Objective:Objective: The aim of this study was to conduct a cost-effectiveness analysis comparing clopidogrel with … rates reported in the CAPRIE trial. The effect of clopidogrel was applied only during the first 2 years of the model …

acetylsalicylic acid (aspirin) and clopidogrel have been shown to reduce the risk of recurrent cardiovascular events in various … subgroups of patients with vascular disease. Objective: To estimate the cost effectiveness of clopidogrel versus aspirin in …. Methods: A Markov model combining clinical, epidemiological and cost data was used to assess the economic value of clopidogrel …

, in periods or patients with elevated risk, more intensive treatment with clopidogrel (alone or together with aspirin) is … compared with aspirin alone and, based on an indirect comparison, also when compared with clopidogrel. Conclusions: The cost … 5 years), and clopidogrel for the treatment of symptomatic cardiovascular disease or acute coronary syndrome (for a …

Background: The PCI-CURE (Percutaneous Coronary Intervention-Clopidogrel in Unstable Angina to Prevent Recurrent Events …) and CREDO (Clopidogrel for the Reduction of Events During Observation) studies have demonstrated that, in addition to … aspirin, pre-treatment with clopidogrel followed by long-term (i.e. 9-12 months) therapy significantly reduces the risk of …